

1013041821

12/04/2001

> d his

(FILE 'HOME' ENTERED AT 11:48:27 ON 16 SEP 2004)

FILE 'REGISTRY' ENTERED AT 11:48:33 ON 16 SEP 2004
E O-DESMETHYLVEN/CN

L1 1 S E4

FILE 'CAPLUS' ENTERED AT 11:49:05 ON 16 SEP 2004

L2 84 S L1
L3 0 S L1/PUR
L4 153160 S PURITY
L5 0 S L4 AND L2

FILE 'USPATFULL' ENTERED AT 11:51:18 ON 16 SEP 2004

L6 24 S L2
SELECT L6 PN 1-24
L7 24 S E1-E28

=> d bib abs 1-84

L7 ANSWER 1 OF 24 USPATFULL on STN
AN 2004:204209 USPATFULL
TI Methods for preparing O-desmethylvenlafaxine
IN Weber, Beat T., Zofingen; SWITZERLAND
PA Wyeth, Madison, NJ, UNITED STATES (non-U.S. corporation)
PI US 2004158101 A1 20040812 <--
AI US 2003-750196 A1 20031231 (10)
RLI Continuation of Ser. No. US 2002-304871, filed on 26 Nov 2002, GRANTED,
Pat. No. US 6689912
PRAI US 2001-334953P 20011204 (60)
DT Utility
FS APPLICATION
LREP WYETH, PATENT LAW GROUP, FIVE GIRALDA FARMS, MADISON, NJ, 07940
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 167
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides an efficient method of making
O-desmethylvenlafaxine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 24 USPATFULL on STN
AN 2004:197404 USPATFULL
TI Use of norepinephrine reuptake modulators for preventing and treating
vasomotor symptoms
IN Deecher, Darlene Coleman, Quakertown, PA, UNITED STATES
Merchenthaler, Istvan Jozsef, Chester Springs, PA, UNITED STATES
Leventhal, Liza, Lawrence, NJ, UNITED STATES
Sipe, Kimberly Jean, King of Prussia, PA, UNITED STATES
O'Connor, Lawrence Thomas, Des Plaines, IL, UNITED STATES
PI US 2004152710 A1 20040805 <--
AI US 2003-685812 A1 20031014 (10)
PRAI US 2002-418591P 20021015 (60)
DT Utility
FS APPLICATION
LREP WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE, 46TH FLOOR, 1650 MARKET
STREET, PHILADELPHIA, PA, 19103
CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 1648

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the use of compounds and composition of compounds that modulate norepinephrine levels for the prevention and treatment of vasomotor symptoms, such as hot flush, caused by, inter alia, thermoregulatory dysfunctions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 24 USPATFULL on STN
AN 2004:190827 USPATFULL
TI Ethers of o-desmethyl venlafaxine
IN Yardley, John P., King of Prussia, PA, UNITED STATES
Abou-Gharbia, Magid A., Exton, PA, UNITED STATES
Ullrich, John W., Exton, PA, UNITED STATES
PA Wyeth, Madison, NJ (U.S. corporation)
PI US 2004147601 A1 20040729 <--
AI US 2003-692542 A1 20031024 (10)
RLI Continuation-in-part of Ser. No. US 2002-315699, filed on 10 Dec 2002,
PENDING Division of Ser. No. US 2001-989000, filed on 21 Nov 2001,
GRANTED, Pat. No. US 6503942 Division of Ser. No. US 2000-722193, filed
on 21 Nov 2000, GRANTED, Pat. No. US 6348494
PRAI US 1999-240922P 19991124 (60)
DT Utility
FS APPLICATION
LREP WYETH, PATENT LAW GROUP, FIVE GIRALDA FARMS, MADISON, NJ, 07940
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 411

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides O- α -acyloxyalkyl ethers of the venlafaxine metabolite 4-[2-(Dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol, represented by Formula (I): ##STR1##

wherein:

the configuration at the stereogenic center (*) may be R, S, or RS (the racemate);

R.sub.1 is selected from C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.6 cycloalkyl, or the moiety: ##STR2##

R.sub.2 is selected from H, or C.sub.1-C.sub.6 alkyl; or,

R.sub.1 and R.sub.2 may be concatenated such that ##STR3##

form a moiety having formula (b): ##STR4##

R3 is selected from H or C.sub.1-C.sub.6 alkyl; and

R4 and R5 are independently selected from H, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6 cycloalkyl, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 thioalkoxy, --CN, --OH, --CF.sub.3, --OCF.sub.3, halogen, --NH.sub.2, --NO.sub.2, or mono or dialkylamino wherein each alkyl group has 1 to 6 carbon atoms, or pharmaceutically acceptable salts or hydrates thereof, R, S, or RS forms thereof; as well as pharmaceutical compositions and methods treating central nervous system disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 24 USPATFULL on STN
AN 2004:185122 USPATFULL
TI Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms

IN Deecher, Darlene Coleman, Quakertown, PA, UNITED STATES
Merchenthaler, Istvan Jozsef, Chester Springs, PA, UNITED STATES
Leventhal, Liza, Lawrenceville, NJ, UNITED STATES
Sipe, Kimberly Jean, King of Prussia, PA, UNITED STATES
O'Connor, Lawrence Thomas, Des Plaines, IL, UNITED STATES

PI US 2004143008 A1 20040722 <--
AI US 2003-684777 A1 20031014 (10)
PRAI US 2002-418591P 20021015 (60)

DT Utility

FS APPLICATION

LREP WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE, 46TH FLOOR, 1650 MARKET STREET, PHILADELPHIA, PA, 19103

CLMN Number of Claims: 21

ECL Exemplary Claim: 1

DRWN 6 Drawing Page(s)

LN.CNT 1446

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the use of compounds and composition of compounds that modulate norepinephrine levels for the prevention and treatment of vasomotor symptoms, such as hot flush, caused by, inter alia, thermoregulatory dysfunctions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 24 USPATFULL on STN

AN 2004:58234 USPATFULL

TI Novel succinate salt of O-desmethyl-venlafaxine

IN Hadfield, Anthony F., Nanuet, NY, UNITED STATES

Shah, Syed M., East Hanover, NJ, UNITED STATES

Winkley, Michael W., Campbell, NY, UNITED STATES

Sutherland, Karen W., New City, NY, UNITED STATES

Provost, James A., Waltham Chase, UNITED KINGDOM

Park, Aeri, West Lafayette, IN, UNITED STATES

Shipplett, Rex A., Wolcott, IN, UNITED STATES

Russell, Brenton W., West Lafayette, IN, UNITED STATES

Weber, Beat T., Zofingen, SWITZERLAND

PA Wyeth, Madison, NJ, UNITED STATES (U.S. corporation)

PI US 2004044241 A1 20040304 <--

AI US 2003-654756 A1 20030904 (10)

RLI Division of Ser. No. US 2002-73743, filed on 11 Feb 2002, GRANTED, Pat. No. US 6673838

PRAI US 2001-297963P 20010613 (60)

US 2001-268214P 20010212 (60)

DT Utility

FS APPLICATION

LREP WYETH, PATENT LAW GROUP, FIVE GIRALDA FARMS, MADISON, NJ, 07940

CLMN Number of Claims: 15

ECL Exemplary Claim: 1

DRWN 12 Drawing Page(s)

LN.CNT 1745

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 24 USPATFULL on STN

AN 2004:25259 USPATFULL

TI Methods of treating gastrointestinal and genitourinary pain disorders

IN Karlstadt, Robyn Gail, Cherry Hill, NJ, UNITED STATES

Lynn, Richard Brian, Bala Cynwyd, PA, UNITED STATES

Burton, Michael Scott, Lansdale, PA, UNITED STATES

Danilewitz, Mervyn, Villanova, PA, UNITED STATES

PA Wyeth, Madison, NJ (U.S. corporation)
PI US 2004019101 A1 20040129 <--
AI US 2003-438572 A1 20030515 (10)
PRAI US 2002-381305P 20020517 (60)
DT Utility
FS APPLICATION
LREP WYETH, PATENT LAW GROUP, FIVE GIRALDA FARMS, MADISON, NJ, 07940
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 299

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a method of treating functional gastrointestinal and genitourinary disorders in a mammal by administering to the mammal an effective amount of a hydroxycycloalkane phenethylamine of the following structural formula: ##STR1##

in which A is a moiety of the formula ##STR2##

where

the dotted line represents optional unsaturation;

R.sub.1 is hydrogen or alkyl;

R.sub.2 is alkyl;

R.sub.4 is hydrogen, alkyl, formyl, or alkanol;

R.sub.5 and R.sub.6 are, independently, hydrogen, hydroxyl, alkyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy;

R.sub.7 is hydrogen or alkyl; and

n is 0, 1, 2, 3, or 4;

or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 24 USPATFULL on STN
AN 2003:335431 USPATFULL
TI Novel formate salt of O-desmethyl-venlafaxine
IN Hadfield, Anthony Francis, Nanuet, NY, UNITED STATES
Winkley, Michael William, Campbell Hall, NY, UNITED STATES
PA Wyeth, Madison, NJ (U.S. corporation)
PI US 2003236309 A1 20031225 <--
AI US 2003-457596 A1 20030609 (10)
PRAI US 2002-387321P 20020610 (60)
DT Utility
FS APPLICATION
LREP WYETH, PATENT LAW GROUP, FIVE GIRALDA FARMS, MADISON, NJ, 07940
CLMN Number of Claims: 53
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 1082

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel salt of O-desmethylvenlafaxine, O-desmethylvenlafaxine formate, is provided. Pharmaceutical compositions, dosage forms and methods of use are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 24 USPATFULL on STN
AN 2003:226440 USPATFULL
TI Ethers of O-Desmethyl venlafaxine
IN Yardley, John P., King of Prussia, PA, UNITED STATES
Abou-Gharbia, Magid A., Princeton Junction, NJ, UNITED STATES
Ullrich, John W., Exton, PA, UNITED STATES
PA Wyeth, Madison, NJ (U.S. corporation)
PI US 2003158253 A1 20030821 <--
AI US 2002-315699 A1 20021210 (10)
RLI Division of Ser. No. US 2001-989000, filed on 21 Nov 2001, GRANTED, Pat.
No. US 6503942 Division of Ser. No. US 2000-722193, filed on 21 Nov
2000, GRANTED, Pat. No. US 6348494
DT Utility
FS APPLICATION
LREP Rebecca R. Barrett, Five Giralda Farms, Madison, NJ, 07940
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 438

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides O- α -acyloxyalkyl ethers of the venlafaxine
metabolite 4-[2-(Dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol,
represented by Formula (I): ##STR1##

wherein:

the configuration at the stereogenic center (*) may be R, S, or RS (the
racemate);

R.sub.1 is selected from C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy,
C.sub.3-C.sub.6 cycloalkyl, or the moiety: ##STR2##

R.sub.2 is selected from H, or C.sub.1-C.sub.6 alkyl; or,

R.sub.1 and R.sub.2 may be concatenated such that ##STR3##

form a moiety having formula (b): ##STR4##

R3 is selected from H or C.sub.1-C.sub.6 alkyl; and

R4 and R5 are independently selected from H, C.sub.1-C.sub.6 alkyl,
C.sub.3-C.sub.6 cycloalkyl, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6
thioalkoxy, --CN, --OH, --CF.sub.3, --OCF.sub.3, halogen, --NH.sub.2,
--NO.sub.2, or mono or dialkylamino wherein each alkyl group has 1 to 6
carbon atoms, or pharmaceutically acceptable salts or hydrates thereof,
R, S, or RS forms thereof; as well as pharmaceutical compositions and
methods treating central nervous system disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 24 USPATFULL on STN
AN 2003:214469 USPATFULL
TI Enantiomers of O-desmethyl venlafaxine
IN Yardley, John P., King of Prussia, PA, UNITED STATES
Asselin, Andre A., Mahwah, NJ, UNITED STATES
PA Wyeth (U.S. corporation)
PI US 2003149112 A1 20030807 <--
AI US 2003-373145 A1 20030224 (10)
RLI Continuation of Ser. No. US 2002-154994, filed on 23 May 2002, ABANDONED
Continuation of Ser. No. US 2001-957908, filed on 21 Sep 2001, ABANDONED
Continuation of Ser. No. US 2000-590741, filed on 8 Jun 2000, ABANDONED
PRAI US 1999-183029P 19990615 (60)
DT Utility

FS APPLICATION
LREP WYETH, PATENT LAW GROUP, FIVE GIRALDA FARMS, MADISON, NJ, 07940
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 590

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides pharmaceutically active enantiomers of the venlafaxine metabolite O-Desmethyl venlafaxine, R(-)-4-[2-(Dimethylamino)-1-(1-hydroxycyclo-hexyl)ethyl]phenol or R(-)-1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclo-hexanol, and S(+)-1-[2-(Dimethylamino)-1-(4-hydroxycyclohexyl)ethyl]cyclohexanol or S(+)-4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol, or one or more pharmaceutically acceptable salts or salt hydrates thereof, as well as pharmaceutical compositions utilizing these enantiomers and methods of using the enantiomers to treat, inhibit or control central nervous system disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 24 USPATFULL on STN
AN 2003:153690 USPATFULL
TI Methods for preparing O-desmethylvenlafaxine
IN Weber, Beat Theodor, Zofingen, SWITZERLAND
PA Wyeth, Madison, NJ, UNITED STATES (non-U.S. corporation)
PI US 2003105358 A1 20030605 <--
US 6689912 B2 20040210
AI US 2002-304871 A1 20021126 (10)
PRAI US 2001-334953P 20011204 (60)
DT Utility
FS APPLICATION
LREP Rebecca R. Barrett, Five Giralda Farms, Madison, NJ, 07940
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 192

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides an efficient method of making O-desmethyl-venlafaxine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 24 USPATFULL on STN
AN 2003:65459 USPATFULL
TI Novel succinate salt of O-desmethyl-venlafaxine
IN Hadfield, Anthony F., Nanuet, NY, UNITED STATES
Shah, Syed M., East Hanover, NJ, UNITED STATES
Winkley, Michael W., Campbell Hall, NY, UNITED STATES
Sutherland, Karen W., New City, NY, UNITED STATES
Provost, James A., Waltham Chase, UNITED KINGDOM
Park, Aeri, West Lafayette, IN, UNITED STATES
Shipplett, Rex A., Wolcott, IN, UNITED STATES
Russell, Brenton W., West Lafayette, IN, UNITED STATES
Weber, Beat T., Zofingen, SWITZERLAND
PA American Home Products Corporation, Madison, NJ (U.S. corporation)
PI US 2003045583 A1 20030306 <--
US 6673838 B2 20040106
AI US 2002-73743 A1 20020211 (10)
PRAI US 2001-268214P 20010212 (60)
US 2001-297963P 20010613 (60)
DT Utility
FS APPLICATION
LREP WYETH, FIVE GIRALDA FARMS, MADISON, NJ, 07940
CLMN Number of Claims: 60

ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 1884

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel salt of O-desmethyl venlafaxine is provided,
O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage
forms and methods of use are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 24 USPATFULL on STN
AN 2003:24240 USPATFULL
TI Methods of treating and preventing pain, anxiety, and incontinence using
derivatives of (-)-venlafaxine
IN Jerussi, Thomas P., Framingham, MA, UNITED STATES
Senanayake, Chrisantha H., Shrewsbury, MA, UNITED STATES
Bhongle, Nandkumar N., Shrewsbury, MA, UNITED STATES
PA Sepracor, Inc. (U.S. corporation)
PI US 2003018083 A1 20030123 <--
AI US 2002-222815 A1 20020819 (10)
RLI Division of Ser. No. US 2001-14592, filed on 14 Dec 2001, GRANTED, Pat.
No. US 6441048 Division of Ser. No. US 1999-450690, filed on 30 Nov
1999, GRANTED, Pat. No. US 6342533
PRAI US 1998-110488P 19981201 (60)
DT Utility
FS APPLICATION
LREP PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000, WASHINGTON, DC,
20006
CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1534

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of preparing, and compositions comprising, derivatives of
(-)-venlafaxine are disclosed. Also disclosed are methods of treating
and preventing diseases and disorders including, but not limited to,
affective disorders such as depression, bipolar and manic disorders,
attention deficit disorder, attention deficit disorder with
hyperactivity, Parkinson's disease, epilepsy, cerebral function
disorders, obesity and weight gain, incontinence, dementia and related
disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 24 USPATFULL on STN
AN 2002:288185 USPATFULL
TI Enantiomers of O-desmethyl venlafaxine
IN Yardley, John P., King of Prussia, PA, UNITED STATES
Asselin, Andre A., Mahwah, NJ, UNITED STATES
PA Wyeth (formerly known as American Home Products Corporation) (U.S.
corporation)
PI US 2002161055 A1 20021031 <--
AI US 2002-154994 A1 20020523 (10)
RLI Continuation of Ser. No. US 2001-957908, filed on 21 Sep 2001, PENDING
Continuation of Ser. No. US 2000-590741, filed on 8 Jun 2000, ABANDONED
PRAI US 1999-183029P 19990615 (60)
DT Utility
FS APPLICATION
LREP WYETH, PATENT LAW GROUP, FIVE GIRALDA FARMS, MADISON, NJ, 07940
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 590

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides pharmaceutically active enantiomers of the venlafaxine metabolite O-Desmethyl venlafaxine, R(-)-4-[2-(Dimethylamino)-1-(1-hydroxycyclo-hexyl)ethyl]phenol or R(-)-1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclo-hexanol, and S(+)-1-[2-(Dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol or S(+)-4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol, or one or more pharmaceutically acceptable salts or salt hydrates thereof, as well as pharmaceutical compositions utilizing these enantiomers and methods of using the enantiomers to treat, inhibit or control central nervous system disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 24 USPATFULL on STN
AN 2002:165272 USPATFULL
TI Methods of treating affective disorders using derivatives of (-)-venlafaxine
IN Jerussi, Thomas P., Framingham, MA, UNITED STATES
Senanayake, Chrisantha H., Shrewsbury, MA, UNITED STATES
Bhongle, Nandkumar N., Shrewsbury, MA, UNITED STATES
PA Sepracor Inc. (U.S. corporation)
PI US 2002086904 A1 20020704 <--
US 6441048 B2 20020827
AI US 2001-14592 A1 20011214 (10)
RLI Division of Ser. No. US 1999-450690, filed on 30 Nov 1999, PATENTED
PRAI US 1998-110488P 19981201 (60)
DT Utility
FS APPLICATION
LREP PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000, WASHINGTON, DC, 20006
CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1543

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of preparing, and compositions comprising, derivatives of (-)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 24 USPATFULL on STN
AN 2002:67269 USPATFULL
TI Ethers of O-Desmethyl venlafaxine
IN Yardley, John P., King of Prussia, PA, UNITED STATES
Abou-Gharbia, Magid A., Princeton Junction, NJ, UNITED STATES
Ullrich, John W., Exton, PA, UNITED STATES
PA American Home Products Corporation, Madison, NJ, UNITED STATES (U.S. corporation)
PI US 2002037922 A1 20020328 <--
US 6503942 B2 20030107
AI US 2001-989000 A1 20011121 (9)
RLI Division of Ser. No. US 2000-722193, filed on 21 Nov 2000, PENDING
PRAI US 1999-240922P 19991124 (60)
DT Utility
FS APPLICATION
LREP AMERICAN HOME PRODUCTS CORPORATION, FIVE GIRALDA FARMS, PATENT LAW, MADISON, NJ, 07940
CLMN Number of Claims: 24

ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 437

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides O- α -acyloxyalkyl ethers of the venlafaxine metabolite 4-[2-(Dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol, represented by Formula (I): ##STR1##

wherein:

the configuration at the stereogenic center (*) may be R, S, or RS (the racemate);

R.sub.1 is selected from C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.6 cycloalkyl, or the moiety: ##STR2##

R.sub.2 is selected from H, or C.sub.1-C.sub.6 alkyl; or,

R.sub.1 and R.sub.2 may be concatenated such that ##STR3##

form a moiety having formula (b): ##STR4##

R3 is selected from H or C.sub.1-C.sub.6 alkyl; and

R4 and R5 are independently selected from H, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6 cycloalkyl, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 thioalkoxy, --CN, --OH, --CF.sub.3, --OCF.sub.3, halogen, --NH.sub.2, --NO.sub.2, or mono or dialkylamino wherein each alkyl group has 1 to 6 carbon atoms, or pharmaceutically acceptable salts or hydrates thereof, R, S, or RS forms thereof; as well as pharmaceutical compositions and methods treating central nervous system disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 16 OF 24 USPATFULL on STN
AN 2002:37942 USPATFULL
TI Enantiomers of O-desmethyl venlafaxine
IN Yardley, John P., King of Prussia, PA, UNITED STATES
Asselin, Andre A., Mahwah, NJ, UNITED STATES
PA American Home Products Corporation, Madison, NJ (U.S. corporation)
PI US 2002022662 A1 20020221 <--
AI US 2001-957908 A1 20010921 (9)
RLI Continuation of Ser. No. US 2000-590741, filed on 8 Jun 2000, ABANDONED
PRAI US 1999-183029P 19990615 (60)
DT Utility
FS APPLICATION
LREP AMERICAN HOME PRODUCTS CORPORATION, FIVE GIRALDA FARMS, PATENT LAW,
MADISON, NJ, 07940
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 588

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides pharmaceutically active enantiomers of the venlafaxine metabolite O-Desmethyl venlafaxine, R(-)-4-[2-(Dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol or R(-)-1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol, and S(+)-1-[2-(Dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol or S(+)-4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol, or one or more pharmaceutically acceptable salts or salt hydrates thereof, as well as pharmaceutical compositions utilizing these enantiomers and methods of using the enantiomers to treat, inhibit or control central nervous system disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 17 OF 24 USPATFULL on STN
AN 2002:34464 USPATFULL
TI Ethers of o-desmethyl venlafaxine
IN Yardley, John P., King of Prussia, PA, United States
Abou-Gharbia, Magid A., Princeton Junction, NJ, United States
Ullrich, John W., Exton, PA, United States
PA American Home Products Corporation, Madison, NJ, United States (U.S. corporation)
PI US 6348494 B1 20020219 <--
AI US 2000-722193 20001121 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Robinson, Binta
LREP Barrett, Rebecca R.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 394

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides O- α -acyloxyalkyl ethers of the venlafaxine metabolite 4-[2-(Dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol, represented by Formula (I): ##STR1##

wherein:

the configuration at the stereogenic center (*) may be R, S, or RS (the racemate);

wherein radicals R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are as defined in the specification; as well as pharmaceutical compositions and methods treating central nervous system disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 18 OF 24 USPATFULL on STN
AN 2002:19350 USPATFULL
TI Derivatives of (-)-venlafaxine and methods of preparing and using the same
IN Jerussi, Thomas P., Framingham, MA, United States
Senanayake, Chrisantha H., Shrewsbury, MA, United States
PA Sepracor, Inc., Marlborough, MA, United States (U.S. corporation)
PI US 6342533 B1 20020129 <--
AI US 1999-450690 19991130 (9)
PRAI US 1998-110488 19981201 (06)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Webman, Edward J.; Assistant Examiner: Nguyen, Helen
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1410

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of preparing, and compositions comprising, derivatives of (-)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 19 OF 24 USPATFULL on STN
AN 2001:33324 USPATFULL
TI Derivatives of (+)-venlafaxine and methods of preparing and using the same
IN Jerussi, Thomas P., Framingham, MA, United States
Senanayake, Chrisantha H., Shrewsbury, MA, United States
PA Sepracor, Inc., Marlborough, MA, United States (U.S. corporation)
PI US 6197828 B1 20010306 <--
AI US 1999-450691 19991130 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Reamer, James H.
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 61
ECL Exemplary Claim: 1,28
DRWN No Drawings
LN.CNT 1555

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of preparing, and compositions comprising, derivatives of (+)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 20 OF 24 USPATFULL on STN
AN 1998:91621 USPATFULL
TI Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression using R enantiomers, S enantiomers, and racemic mixtures of selective serotonin reuptake inhibitor compounds or their active metabolites
IN Dodman, Nicholas H., Grafton, MA, United States
PA Trustees of Tufts College, Medford, MA, United States (U.S. corporation)
PI US 5788986 19980804 <--
AI US 1996-699112 19960816 (8)
RLI Continuation-in-part of Ser. No. US 1995-417747, filed on 6 Apr 1995, now patented, Pat. No. US 5554383
DT Utility
FS Granted
EXNAM Primary Examiner: Azpuru, Carlos
LREP Prashker, David
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1254

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A veterinary method for clinically modifying the behavior of a household pet dog exhibiting a recognized type of canine affective aggression behavior is provided. The veterinary behavior modification method administers at least one compound selected from the group consisting of R enantiomers, S enantiomers, or a racemic mixture of selective serotonic reuptake inhibitors or their active metabolites to the dog upon one or multiple occasions; and the administration of these compounds will modify clinically the canine affective aggression behavior of the household dog permanently or for an indefinite period of time. This veterinary behavior modification method can be usefully employed as an adjunct to conditioning approaches presently employed and will avoid the need for euthanasia in extreme behavioral circumstances.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 21 OF 24 USPATFULL on STN
AN 91:69018 USPATFULL
TI Preparation of cyclohexanol derivatives and novel thioamide intermediates
IN Shepard, Robin G., Windsor, England
PA John Wyeth & Bro., Limited, Maidenhead, England (non-U.S. corporation)
PI US 5043466 19910827 <--
AI US 1990-471187 19900126 (7)
PRAI GB 1989-2209 19890201
DT Utility
FS Granted
EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: Rand, Scott C.
LREP Seifert, Arthur G.
CLMN Number of Claims: 14
ECL Exemplary Claim: 8
DRWN No Drawings
LN.CNT 256

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The preparation of compounds having the formula I ##STR1## where R.sup.1 is --CN, --CO--N(CH.sub.3).sub.2 or --CS--N(CH.sub.3).sub.2 and R.sup.2 is hydrogen, methyl or a removable protecting group is carried out by condensing a compound having the formula ##STR2## where M is lithium, sodium, potassium or halomagnesium and R.sup.3 is methyl or a removable protecting group in a solvent comprising 80-100% of one or more hydrocarbons and 0-20% of one or more ethers.

The solvent enables less inconvenient reaction temperatures to be used and higher yields to be obtained. Compounds (I) are new per se where R.sup.1 is --CS--N(CH.sub.3).sub.2. Compounds (I) are chemical intermediates for preparing N,N-dimethyl-2-(1-hydroxycyclohexyl)-2-(4-hydroxyphenyl or 4-methoxyphenyl) ethylamine and pharmaceutically acceptable salts thereof. These end products are antidepressants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 22 OF 24 USPATFULL on STN
AN 88:48848 USPATFULL
TI Substituted phenylacetamides
IN Husbands, G. E. Morris, Berwyn, PA, United States
Yardley, John P., Gulph Mills, PA, United States
Muth, Eric A., West Chester, PA, United States
PA American Home Products Corporation, New York, NY, United States (U.S. corporation)
PI US 4761501 19880802 <--
AI US 1985-736744 19850522 (6)
RLI Division of Ser. No. US 1983-545701, filed on 26 Oct 1983, now patented, Pat. No. US 4535186, issued on 13 Aug 1985 which is a continuation-in-part of Ser. No. US 1983-486594, filed on 19 Apr 1983, now abandoned which is a continuation-in-part of Ser. No. US 1982-449032, filed on 13 Dec 1982, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Higel, Floyd D.; Assistant Examiner: Greason, Carolyn S.
LREP Jackson, Richard K.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1127

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This application discloses certain substituted phenylacetamides of the formula: ##STR1## in which the dotted line represents optional unsaturation, R.sub.1 is alkyl;

R.sub.2 is alkyl;

R.sub.4 is hydrogen or alkyl; R.sub.5 and R.sub.6, one of which may be hydrogen, are independently, hydroxyl, alkyl, alkoxy, aralkoxy, alkanoyloxy, alkylmercapto, N-protected amino, halo or trifluoromethyl;

R.sub.7 is hydrogen or alkyl; and

n is one of the integers 0, 1, 2, 3 or 4;

which are useful in the production of antidepressant agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 23 OF 24 USPATFULL on STN
AN 86:51087 USPATFULL
TI Substituted phenylacetone nitriles
IN Husbands, G. E. Morris, Berwyn, PA, United States
Yardley, John P., Gulph Mills, PA, United States
Muth, Eric A., West Chester, PA, United States
PA American Home Products Corporation, New York, NY, United States (U.S. corporation)
PI US 4611078 19860909 <--
AI US 1985-736747 19850522 (6)
RLI Division of Ser. No. US 1983-545701, filed on 26 Oct 1983, now patented, Pat. No. US 4535186 which is a continuation-in-part of Ser. No. US 1983-486594, filed on 19 Apr 1983, now abandoned which is a continuation-in-part of Ser. No. US 1982-449032, filed on 13 Dec 1982, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Torrence, Dolph H.
LREP Jackson, Richard K.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1069

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This application discloses certain substituted phenylacetone nitriles of the formula: ##STR1## in which the dotted line represents optional unsaturation, and R.sub.4 is hydrogen or alkyl;

R.sub.5 and R.sub.6, one of which may be hydrogen, are ortho or para substituents, independently selected from the group consisting of hydroxyl, alkyl, alkoxy, aralkoxy, alkanoyloxy, alkylmercapto, halo or trifluoromethyl;

R.sub.7 is hydrogen or alkyl; and

n is one of the integers 0, 1, 2, 3 or 4;

which are useful in the production of antidepressant agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 24 OF 24 USPATFULL on STN
AN 85:47832 USPATFULL
TI 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
IN Husbands, G. E. Morris, Berwyn, PA, United States

Yardley, John P., Gulph Mills, PA, United States
Muth, Eric A., West Chester, PA, United States
PA American Home Products Corporation, New York, NY, United States (U.S.
corporation)
PI US 4535186 19850813 <--
AI US 1983-545701 19831026 (6)
RLI Continuation-in-part of Ser. No. US 1983-486594, filed on 19 Apr 1983,
now abandoned which is a continuation-in-part of Ser. No. US
1982-449032, filed on 13 Dec 1982, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Chan, Nicky
LREP Jackson, Richard K.
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1171

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a group of hydroxycycloalkanephenethyl amine
antidepressant derivatives of the following structural formula: ##STR1##
in which A is a moiety of the formula ##STR2## where the dotted line
represents optional unsaturation;

R.sub.1 is hydrogen or alkyl;

R.sub.2 is alkyl;

R.sub.4 is hydrogen, alkyl, formyl or alkanoyl;

R.sub.5 and R.sub.6 are, independently, hydrogen, hydroxyl, alkyl,
alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino,
dialkylamino, alkanamido, halo, trifluoromethyl or, taken together,
methylenedioxy;

R.sub.7 is hydrogen or alkyl; and


n is 0, 1, 2, 3 or 4;

or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 93413-62-8 REGISTRY
 CN Phenol, 4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol
 CN Desvenlafaxine
 CN DVS 233
 CN **O-Desmethylvenlafaxine**
 FS 3D CONCORD
 DR 130198-07-1
 MF C16 H25 N O2
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOSIS, CA, CANCERLIT, CAPLUS, CASREACT, CHEMCATS, HSDB*, IMSPATENTS, IMSRESEARCH, MEDLINE, PHAR, PROUSDDR, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
 RLD.NP Roles for non-specific derivatives from non-patents: FORM (Formation, nonpreparative)



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

84 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 84 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>